RobertWilliamWeberMD

PubMed

• 6 citations
  Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.
  Craig L. Slingluff, Karl D. Lewis, Robert H.I. Andtbacka, John R. Hyngstrom, Mohammed M. Milhem, Svetomir N. Markovic, Tawnya L. Bowles, Omid Hamid, Leonel Hernandez-A...> ;Journal for Immunotherapy of Cancer. 2021 Oct 1
• Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma.
  Spitler, L. E.,Boasberg, P.,O'Day, S.,Hamid, O.,Cruickshank, S.,Mesko, S.,Weber, R. W.> ;Am. J. Clin. Oncol.. 2015 Jan 24
• Biological Effects of Anti-Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Antibody Formation in Patients Treated With GM-CSF (Sargramostim) as Adjuvant Ther...
  Spitler, L. E.,Cao, H.,Piironen, T.,Whiteside, T. L.,Weber, R. W.,Cruickshank, S.> ;Am. J. Clin. Oncol.. 2014 Oct 07
• Brentuximab Vedotin: First-line Agent for Advanced Hodgkin Lymphoma.
  Cao, H.,Yamamoto, K.,Yang, L. X.,Weber, R.> ;Anticancer Res.. 2013 Sep
• Phase II trial of nab-paclitaxel and bevacizumab as first-line therapy in patients with unresectable melanoma.
  Boasberg PD, Weber RW, Cruickshank S, Hamid O, O'Day S, Spitler LE> ;J. Clin. Oncol.. 2011-05-20
• Immunological effects and clinical outcomes in patients with high-risk melanoma given adjuvant therapy with granulocyte-macrophage colony stimulating factor (GM-CSF, s...
  Spitler LE, Weber RW, Cruickshank S, Whiteside TL> ;J. Clin. Oncol.. 2009-05-20
• Granulocyte-macrophage colony stimulating factor (GM-CSF, sargramostim) as adjuvant therapy of melanoma.
  Spitler LE, Weber RW, Cruickshank S, Thompson JF, Lin H, Soong SJ, Garbe E, Ernstoff MS, Grossbard ML, Markovic SN, Whiteside TL> ;J. Clin. Oncol.. 2008-05-20
• 25 citations
  Low-Dose Outpatient Chemobiotherapy With Temozolomide, Granulocyte-Macrophage Colony Stimulating Factor, Interferon-α2b, and Recombinant Interleukin-2 for the Treatmen...
  R. W. Weber, Steven J. O'Day, Madalene Rose, Regina Deck, Patricia Ames, James Good, John Meyer, Robert C. Allen, Sharon Trautvetter, Molly Timmerman, Scott Cruickshan...> ;Journal of Clinical Oncology. 2005 Dec 10
• A phase I study of granulocyte macrophage colony-stimulating factor (GM-CSF) and escalating doses of thalidomide in patients with high-risk malignant melanoma.
  Lutzky J, Weber R, Nunez Y, Menendez M, Rose M, Trautvetter S, Timmerman M, Spitler LE> ;J. Clin. Oncol.. 2005-06-01
• Phase II study of low-dose outpatient chemobiotherapy with temozolomide (TMZ), granulocyte macrophage colony stimulating factor (GM-CSF), Interferon-alpha-2b (IFN), an...
  Weber RW, O'Day S, Rose M, Ames P, Good J, Meyer J, Allen R, Trautvetter S, Timmerman M, Gonzalez R, Spitler LE> ;J. Clin. Oncol.. 2005-06-01
• 80 citations
  Merkel cell carcinoma: review of 22 cases with surgical, pathologic, and therapeutic considerations.
  Russell Gollard, Robert Weber, Michael P. Kosty, Hubert T. Greenway, Vincent Massullo, Cora Humberson> ;Cancer. 2000 Apr 15
• Join now to see all